Detalhe da pesquisa
1.
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts.
Cancer Discov
; 13(11): 2432-2447, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37623743